Filing Flows › Health Care › CapForce (CFOR)
CapForce (CFOR) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 19, 2026 · CapForce (CFOR) Q2 2026 earnings results →
Q2 2026 Revenue up 1150% year over year to $50.0M · 85¢ of every $1 of revenue kept as net profit · operating margin 88.6%
CapForce made $50.0M in Q2 2026 (12× Y/Y). Operating margin 88.6%, net earnings $42.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 19, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $50.0M in Q2 2026, up 1150% year over year.
Operating profit was $44.3M, a 88.6% margin (up 3.5 points year over year). Of the extra revenue versus Q2 2025, 89% reached operating profit, above the 85% margin then. Total costs grew 857% against revenue growth of 1150%. The fastest-growing cost line was General & admin (+20%). Net earnings were $42.5M, up 1110% year over year. The effective tax rate was 4.3%.
Operating cash flow was −$618K. Non-cash charges added back $52K of depreciation and amortization and $69K of share-based compensation. Working capital and other items used $43.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 19, 2026 | $50.0M | 12× | 88.6% | $42.5M | −$618K |
| Q4 2025 | 10-K | May 26, 2026 | $26.2M | +424% | 83.4% | $21.1M | −$205K |
| Q2 2025 | 10-Q | Oct 31, 2025 | $4.0M | 143× | 85.1% | $3.5M | −$447K |
| Q4 2024 | 10-K | Aug 21, 2025 | $5.0M | +367% | 88.0% | $4.4M | −$232K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About CapForce
Please refer to the Glossary at the end of this Business section for definitions or descriptions of industry, regulatory, and CapForce-specific terms used in this Annual Report. CapForce Inc. (“CapForce” or the “Company”, formerly known as OpGen, Inc.) was incorporated in Delaware in 2001. From inception through November 2023, the Company operated as a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company, along with its subsidiaries, Curetis GmbH (“Curetis”) and Ares Genetics GmbH (“Ares Genetics”), developed and commercialized molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life-threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.
In its own words, from its 10-K, filed May 26, 2026.
CapForce against its Services-Medical Laboratories peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: 12× against the peers' median +25%. Operating margin: 88.6% against the peers' median 7.0%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CFOR CapForce | Q2 2026 | $50.0M | 12× | 88.6% |
| LH Labcorp Holdings | Q3 2026 | $3.8B | +7% | 10.6% |
| DGX Quest Diagnostics | Q3 2026 | $3.1B | +10% | 15.5% |
| NTRA Natera | Q3 2026 | $794M | +34% | -8.6% |
| FTRE Fortrea Holdings | Q3 2026 | $692M | -1% | 2.2% |
| RDNT RadNet | Q2 2026 | $623M | +25% | 6.3% |
| GH Guardant Health | Q3 2026 | $361M | +36% | -36.8% |
| CAI Caris Life Sciences | Q3 2026 | $275M | +27% | 7.0% |
| LMRI Lumexa Imaging Holdings | Q2 2026 | $264M | +5% | 8.7% |
Source: CapForce 10-Q on SEC EDGAR · CIK 1293818 · Services-Medical Laboratories
More on CFOR
History
Every quarter: Q2 2026 results · Q4 2025 results · Q2 2025 results · Q4 2024 results